11 Best Growth Stocks to Invest in According to Billionaires

In this article, we will explore the best growth stocks to invest in according to billionaires.

Infotech and biotech remain two of the clearer growth pockets because the underlying spending data is still expanding. In infotech, Gartner said worldwide IT spending is projected to reach $6.15 trillion in 2026, up 10.8% from 2025. Within that, data center systems are expected to rise 31.7% to $653.4 billion, software 14.7% to $1.43 trillion, and server spending 36.9% year over year, which places growth squarely in AI infrastructure and enterprise software rather than in slower device categories.

Biotech is standing in a different but still measurable growth phase. On the product side, the FDA said CDER approved 46 novel drugs in 2025, showing continued output in new therapies. On the capital side, IQVIA reported that biopharma funding increased for a second straight year and that clinical trial starts have returned to pre-pandemic levels, while EY said life sciences M&A reached $240 billion in 2025, up 81% in value from 2024.

The outlook, based on those same sources, is continued IT growth led by AI-linked spending and continued biotech activity supported by approvals, funding, trials, and dealmaking rather than by broad-based exuberance.

Methodology

We used screeners to narrow down to stocks with a forward revenue CAGR over 25%, and, among these, picked the ones that the highest number of billionaires were holding as of Q4, 2025. We then limited our selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among elite hedge funds and Wall Street analysts.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

11. Guardant Health, Inc. (NASDAQ:GH)

Guardant Health, Inc. (NASDAQ:GH) is one of the best growth stocks to buy according to billionaires.

As of March 13, 2026, Guardant Health carried a Moderate Buy consensus from 23 analysts, based on 21 Buy ratings, one Hold, and one Sell. The average 12-month price target stood at $122.57, implying about 43% upside from the recent share price of $85.49, while the published target range ran from $55 to $180.

The bullish tone came after a stretch of company updates that gave analysts more to work with than a single earnings print. On February 19, 2026, Guardant Health reported fourth-quarter 2025 revenue of $281.3 million, up 39% year over year, with oncology revenue rising 30% to $189.9 million and screening revenue reaching $35.1 million. The company said it expects total 2026 revenue to grow 27% to 30%.

Management then added more detail at the Leerink Global Healthcare Conference on March 10, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 11, 2026. At those events, Guardant highlighted its Quest Diagnostics partnership as a key commercial lever for Shield and said any upside from Quest’s co-promotion was not included in 2026 guidance. The company also said 90% of Shield users had not been screened in the prior five years, reinforcing its view that Shield can expand the screening market rather than just compete within it. Management also pointed to further portfolio catalysts, including potential FDA-related progress tied to ESR1 monitoring in Guardant360, while noting that Reveal Ultra was excluded from 2026 guidance because reimbursement remains uncertain.

Against that backdrop, Piper Sandler analyst David Westenberg maintained a Buy rating and $130 price target on March 11, 2026, after raising his target from $120 to $130 on February 24, 2026, following the company’s quarterly release.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company that develops blood-based tests for cancer screening, treatment selection, and recurrence monitoring.

10. CoreWeave, Inc. (NASDAQ:CRWV)

CoreWeave, Inc. (NASDAQ:CRWV) is one of the best growth stocks to invest in according to billionaires.

As of March 13, CoreWeave carries a consensus analyst rating of “Moderate Buy” based on 32 Wall Street ratings, with 18 buy ratings, 12 hold ratings, and 2 sell ratings. The average 12-month price target sits at $122.35, implying about 50.9% upside from the referenced share price of $81.11. The stock has also drawn heavy analyst attention lately.

The backdrop was followed by Evercore ISI’s March 9, 2026, rating action on the stock. Evercore ISI analyst Amit Daryanani lowered the firm’s price target on CoreWeave to $120 from $150 while maintaining an Outperform rating. The publicly available summary said the revision followed a “deep dive into new project margin builds,” suggesting the firm remained constructive on the company’s positioning while taking a more measured view of project-level economics.

For context, CoreWeave has continued to announce projects and platform expansions. On March 10, the company introduced Flexible Capacity Plans, adding Flex Reservations and Spot offerings to its capacity framework for AI workloads. Earlier, on March 4, CoreWeave announced a strategic partnership with Perplexity to support the latter’s AI inference workloads on CoreWeave Cloud and to pilot new services across both organizations.

Moreover, in October, 2025, the company announced it would provide Poolside with a cluster of NVIDIA GB300 NVL72 systems, including more than 40,000 GPUs, while also planning to support Poolside’s Project Horizon campus in West Texas. The company also joined the Department of Energy’s Genesis Mission in December, expanding its role in public-sector and research-oriented AI infrastructure.

CoreWeave, Inc. (NASDAQ:CRWV) is an AI cloud infrastructure company that provides compute capacity, software tools, and related services designed for AI model training and inference. Founded in 2017, the company operates a purpose-built cloud platform for AI customers across enterprise, startup, and public-sector markets.

9. Rivian Automotive, Inc. (NASDAQ:RIVN)

Rivian Automotive, Inc. (NASDAQ:RIVN) is one of the best growth stocks to invest in according to billionaires.

On March 10, 2026, TD Cowen analyst Itay Michaeli upgraded Rivian Automotive, Inc. (NASDAQ:RIVN) to Buy from Hold and raised their price target to $20 from $17. Public reporting on the note said the upgrade was tied mainly to the expected launch of Rivian’s lower-priced R2 platform, which TD Cowen sees as a potentially important volume driver relative to the company’s current higher-priced R1 vehicles. Reported estimates tied to the note put potential long-run annual demand for the R2 at roughly 212,000 to 335,000 units.

That context is relevant because Rivian has already been laying out the R2 as its next major product step. On March 12, the company disclosed the R2 lineup and pricing, including a launch variant starting at $57,990, with additional trims to follow and an entry configuration expected at $45,000.

Rivian’s recent operating results also help explain why the R2 matters. The company delivered 42,247 vehicles in 2025, and in its February 12, 2026, full-year results release, it reported $144 million in consolidated gross profit for 2025, compared with a gross loss of $1.2 billion in 2024. Rivian also guided for 62,000 to 67,000 vehicle deliveries in 2026.

Rivian Automotive, Inc. (NASDAQ:RIVN) designs and manufactures electric vehicles and related software and services. Its current consumer lineup includes the R1T pickup and R1S SUV, while the R2 is positioned as a smaller, more affordable model aimed at broadening the company’s addressable market.

8. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best growth stocks to buy according to billionaires.

As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street. Based on 21 analyst targets, the average price target stood at $89.00, with a high target of $110.00 and a low target of $39.00. Using the share price in that March 13 snapshot, the average target implied roughly 25% upside.

The bullish stance came as Ionis entered 2026 with a fuller commercial and pipeline story than a simple rating change might suggest. On February 25, 2026, the company reported full-year 2025 revenue of $944 million, up 34% from 2024, helped by the commercial launch of TRYNGOLZA and a $280 million upfront payment from Ono Pharmaceutical. Ionis also said it expects 2026 revenue of $800 million to $825 million on a like-for-like basis and ended 2025 with $2.7 billion in cash, cash equivalents, and short-term investments.

Management then added more context at investor conferences in March. At the TD Cowen conference on March 2, 2026, Ionis said TRYNGOLZA had received priority review for severe hypertriglyceridemia, with a June 30, 2026, PDUFA date, and indicated that 2026 guidance for the product could be updated after the first quarter. At the Leerink conference on March 9, 2026, the company said TRYNGOLZA generated $108 million in 2025 revenue and projected U.S. peak sales above $2 billion. Ionis also pointed to several 2026 catalysts, including Phase 3 readouts tied to CARDIO-TTRansform and Novartis-partnered pelacarsen in HORIZON. At the Barclays conference on March 11, 2026, management again described 2026 as a transformational year with multiple launches, approvals, and late-stage readouts ahead.

Against that backdrop, Leerink analyst Mani Foroohar maintained an Outperform rating on March 3, 2026, and raised his price target to $104 from $102.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a biotechnology company focused on discovering and developing RNA-targeted medicines for serious diseases. The company says its platform is built around advancing treatments across neurology, cardiology, and other specialty areas.

7. Bloom Energy Corporation (NYSE:BE)

Bloom Energy Corporation (NYSE:BE) is one of the best growth stocks to invest in according to billionaires.

As of March 13, 2026, Bloom Energy Corporation (NYSE:BE) had a mixed Wall Street setup, with 26 analysts assigning 11 Buy ratings, 12 Hold ratings, and 3 Sell ratings. The average 12-month price target stood at $131.87, with published targets ranging from $10 to $207.

The stock’s recent coverage came against a broader backdrop of rising interest in power suppliers tied to AI infrastructure. On March 3, 2026, Melius Research said Bloom was seeing a surge in fuel-cell demand from AI datacenters, noting a 2.5x increase in product backlog and a 1.5x increase in service backlog over the past year. Melius also argued Bloom has an advantage because fuel-cell systems can be delivered in months rather than years, which matters as large datacenter operators look for faster ways to secure power.

That theme remained in focus on March 10, 2026, when Morgan Stanley said AI infrastructure demand continued to grow despite rising concerns around the sector, and listed Bloom among stocks positioned to benefit as power remains one of the main bottlenecks in the AI buildout.

Against that backdrop, Citigroup initiated coverage on February 24, 2026, with a Neutral rating and a $162 price target. The call followed Bloom Energy’s February 5, 2026, fourth-quarter release, when the company reported revenue of $777.7 million, up 35.9% year over year, and non-GAAP diluted EPS of $0.45. For the full year 2025, revenue rose 37.3% to $2.02 billion. Bloom also guided for 2026 revenue of $3.1 billion to $3.3 billion and non-GAAP EPS of $1.33 to $1.48.

Bloom Energy Corporation (NYSE:BE) makes solid oxide fuel cell systems for on-site power generation and serves customers across data centers, utilities, and commercial and industrial markets.

6. Palantir Technologies Inc. (NASDAQ:PLTR)

Palantir Technologies Inc. (NASDAQ:PLTR) is one of the best growth stocks to invest in according to billionaires.

On March 12, 2026, Palantir said it had entered a strategic partnership with Ondas Inc. and World View Enterprises to develop and deploy AI-enabled capabilities for persistent intelligence, surveillance, and reconnaissance missions across the stratosphere, air, and land domains. According to the company’s press release, the effort will combine Palantir’s Artificial Intelligence Platform with World View’s Stratollite high-altitude sensing platform and Ondas’ unmanned aerial, ground, and counter-drone systems to build a unified intelligence and command-and-control architecture.

Palantir said the companies plan to develop three core programs together. The first, Palantir Warp Speed, is meant to connect supply chain, engineering, manufacturing, and mission operations data to support production scaling for World View’s Stratollite fleet. The second, AI Flight Director, is designed to support mission planning and operations by combining atmospheric data, telemetry, proprietary modeling, and historical mission data. The third, SkyWeaver, is focused on edge computing onboard Stratollite systems to allow intelligence processing closer to the mission environment and reduce latency in degraded-connectivity conditions.

Palantir added that work to optimize World View’s stratospheric systems is already underway, with integration across Ondas’ broader portfolio expected to begin as early as the fourth quarter of 2026.

Palantir Technologies Inc. (NASDAQ:PLTR) builds software platforms for government and commercial customers, with products focused on data integration, operational decision-making, and artificial intelligence.

Click to continue reading and see the 5 Best Growth Stocks to Invest In According to Billionaires.

Disclosure: None. Follow Insider Monkey on Google News.